Initiating Treatment
Active Resources: 12
Online and Self-Paced Learning
-
11/8/2017
Antiretroviral Guidelines
-
10/27/2017
Online Training
-
10/20/2017
-
8/23/2017
-
9/15/2016
Slide Sets
-
4/28/2017
Toolkits
-
5/17/2016
Image Library
-
4/6/2016
Charts, Tables & Posters
-
1/28/2015
-
6/1/2013 (reviewed: 1/11/2017)
Patient Information
-
9/29/2013 (reviewed: 2/24/2017)
Archive Resources: 4
Antiretroviral Guidelines
-
3/5/2012
Self-Study Materials
-
3/1/2010
Slide Sets
-
1/1/2006
Patient Information
-
1/1/2005
Articles: 6
-
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (...
-
Bictegravir in Initial Therapy
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...
-
Adult and Adolescent Guidelines: Major Changes
The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy.
Efavirenz/TDF/FTC (Atripla) has... -
Darunavir + Raltegravir without NRTIs: NEAT Study Results
Over the past few years, numerous studies have examined the use of NRTI-sparing regimens in initial therapy. These regimens generally have not been as effective as standard regimens, for reasons that are not entirely clear, or have had higher rates of toxicity. Two small studies...
-
First-Line Therapy: Raltegravir, Darunavir, or Atazanavir?
ACTG 5257 is a randomized open-label comparison of 3 ARV regimens for initial therapy: atazanavir + ritonavir (ATV/r), darunavir + ritonavir (DRV/r), or raltegravir (RAL), each in combination with fixed-dose tenofovir/emtricitabine.
The 3 treatment groups (...
| Day | Title |
|---|---|
|
6/13 |
Faith-Based HIV Symposium
Event type: Conferences & Events
|
|
12/2 |